Vmbook Online ordering

Inovio Pharmaceuticals Inc

Inovio Pharmacethicals, Inc is a publicly-traded company listed on the Nasdaq stock exchange under the ticker symbol INO.

The company is a biotechnology organization focusing on creating and developing DNA-based immunotherapies and vaccines for treating and preventing various cancers and infectious diseases.

Inovio's lead product candidate is VGX-100, an investigational immunotherapy treating precancerous cells caused by human papillomavirus (HPV). The company is also developing vaccine candidates for treating cancer types, including ovarian, head and neck, and lung cancers.

Inovio has collaborated with several pharmaceutical companies, government agencies, and non-profit organizations to advance its product candidates through clinical trials and potentially commercialize them.

Inovio Pharmaceuticals has been publicly traded since May 2010, and its stock price has experienced significant volatility due to the company's clinical trial results and the overall biotechnology sector's up-and-down performance.

The company has raised capital through stock offerings and partnerships to fund its clinical trials and R&D activities. The company has a strong patent portfolio, including multiple issued and pending patents on its DNA-based vaccine and immunotherapy technology.

Inovio has received regulatory approval to initiate clinical trials of its products in several countries, including the United States, Canada, and China. The company has also received Breakthrough Therapy designation from the FDA for its lead product candidate, VGX-100.